Abstract
Four heterocyclic embedded Schiff base derivatives (1–4) were synthesized and characterized by melting point, elemental analysis, FTIR, 1H, 13C NMR, UV–Visible spectral data. The structures of compounds 1, 2 and 4 were successfully established through single crystal X-ray diffraction analysis. In vitro cholinesterase inhibition assays showed that the cyclized derivative 1 displayed higher BuChE enzyme inhibitory activity with IC50 value of 1.45 ± 0.09 μM. The anti-proliferative efficacies of the compounds were also evaluated using human colorectal HCT 116 and breast MCF-7 adenocarcinoma cell lines. In addition, a human normal endothelial cell line (Ea.hy926) was also tested to assess the safety and selectivity of the compounds towards normal and cancer cells, respectively. Among the compounds tested, compound 2 displayed potent cytotoxic effect (IC50 = 34 μM) against HCT 116 cells with highest selectivity index of 3.1 with respect to the normal endothelial cells. Whereas, compound 4 exhibited significant anti-proliferative effect (IC50 = 21.1 μM) against MCF-7 cells with highest selectivity index of 3.3 with respect to the normal endothelial cells. The docking result of these compounds against hAChE showed potent activities with different binding modes. These compounds could be a promising pharmacological agent to treat cancer and Alzheimer's disease.
[Display omitted]
•Four new Schiff base compounds were synthesized and fully characterized.•Compound 1 showed good BuChE enzyme inhibitory activities (IC50 1.45 ± 0.09 μM).•Compound 4 showed antiproliferative effect (IC50 21.1 μM) against MCF-7 (SI 3.3).•Compound 2 exhibited IC50 34 μM against HCT 116.